Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:57 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
MR and Inflammation After Preeclampsia
NCT07345845 · Anna Stanhewicz, PhD · EARLY_PHASE1 · withdrawn · last registry update 2026-10-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Trainee project; study never initiated” | – | Registry record, Anna Stanhewicz, PhD |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against NR3C2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-27Phase 3 first posted: The George Institute, Fludrocortisone 50 mcg daily + Fludrocortisone 100 mcg daily (NCT07898462)
- 2026-10-27Results posted on the registry: Bayer, Finerenone (NCT05901831)
- 2026-10-23Phase 3 first posted: Massachusetts General Hospital, Eplerenone + Placebo (NCT07892664)
- 2026-10-06Also stopped (terminated): Boehringer Ingelheim, BI 3031185 + Placebo matching BI 3031185 (NCT07656792)
- 2026-09-29Results posted on the registry: Yale University, Intravenous digoxin (NCT05014087)
- 2026-09-29Also stopped (terminated): Yale University, Intravenous digoxin (NCT05014087)
- 2026-09-22Also stopped (withdrawn): Sarfez Pharmaceuticals, Inc., Combination Product: FDC of spironolactone and ER torsemide + Combination Product: Stabilized doses of loop diuretic and finerenone (NCT07223502)
- 2026-09-18Phase 3 first posted: Central Hospital, Nancy, France, Eplerenone (NCT07828223)
- 2026-09-15Results posted on the registry: ReveraGen BioPharma, Inc., Vamorolone + Placebo (NCT05166109)
- 2026-09-15Results posted on the registry: Brigham and Women's Hospital, Eplerenone + Chlorthalidone with potassium chloride (NCT04519164)
- 2026-08-31Also stopped (withdrawn): CAMC Health System, Hydrocortisone + Fludrocortisone (NCT00368381)
- 2026-07-27Phase 3 first posted: Xinjiang Medical University, Eplerenone + Placebo (NCT07727252)
- 2026-07-13Results posted on the registry: Bayer, Finerenone (BAY94-8862 ) 10 mg + Empagliflozin (NCT05254002)
- 2026-07-06Phase 3 first posted: Beni-Suef University, Dapagliflozin (NCT07684326)
- 2026-05-20Phase 3 first posted: Chittagong Medical College, Dapagliflozin +Finerenone arm + Dapagliflozin arm (NCT07598864)
- 2026-05-08Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Finerenone + Placebo (NCT07575672)
- 2026-05-06Phase 3 first posted: Washington University School of Medicine, HFrEF Polypill (NCT07569640)
- 2026-04-17Phase 3 first posted: Dr. Hang Wun Raymond Li, Estetrol-drospirenone + Ethinylestradiol-levonorgestrel (NCT07536763)
- 2026-01-21Phase 3 first posted: kewen Chen,MD, Experimental Group + Control (Standard treatment) (NCT07356388)
- 2025-12-15Results posted on the registry: Santhera Pharmaceuticals, Vamorolone + Midazolam (NCT06689527)
- 2025-12-11Also stopped (terminated): Jinling Hospital, China, Finerenone (BAY 94-8862) + Empagliflozin 10 mg (NCT06818305)
- 2025-12-08Phase 3 first posted: Subodh Verma, Finerenone + Placebo (NCT07270367)
- 2025-11-14Results posted on the registry: University of California, San Francisco, Yasmin (NCT03819140)
- 2025-11-06Also stopped (withdrawn): Brigham and Women's Hospital, Eplerenone + Placebo (NCT01794091)
- 2025-11-04Results posted on the registry: University of Texas Southwestern Medical Center, Abiraterone acetate (NCT02574910)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision